Honesty Management
StemCyte prioritizes corporate governance and is committed to sustainable growth and integrity-driven management.
Implementation Status of the Integrity Management Policy
- The Company has established a Code of Integrity Management and a Code of Ethical Conduct, requiring Board members and management to actively implement the integrity management policy and to strengthen employee awareness.
- In August 2024, briefings on corporate governance and securities regulations were provided to directors, and we arranged for them to attend courses related to corporate governance and integrity management. New hires receive training on the Code of Integrity Management during onboarding so that integrity-related policies are communicated from the outset. We also hold corporate social responsibility trainings from time to time to clarify employees’ rights and obligations and to deepen understanding of the integrity policy.
- The Company has adopted Insider Trading Prevention Procedures that define the scope, covered persons, and related operating processes to prevent directors, officers, and other insiders from inadvertently or intentionally violating insider-trading regulations, thereby protecting investors and the Company.
- On November 29, 2024, the Company conducted an insider-trading awareness session for all employees (64 participants). Topics included insider shareholdings and reporting, the elements and common patterns of short-swing trading, the elements of insider trading, legal liabilities, and relevant case studies.
- In our annual courses on the prohibition of insider trading, directors are reminded not to trade the Company’s shares during blackout periods—thirty (30) days before the announcement of the annual financial statements and fifteen (15) days before the announcement of each quarterly financial report.
- The Company has established reporting channels, including an email reporting option.
Reporting email: stemcytebio-hr@stemcytebio.com
Reporting email: